Immunology and Immunotherapy
Behnam Badie, M.D.
Behnam Badie, M.D., The Heritage Provider Network Professor in Gene Therapy, professor and chief of the Division of Neurosurgery, received his M.D. from University of California Los Angeles. His research focuses on exploring novel immunotherapeutic strategies through the activation of microglia and macrophages to treat malignant brain tumors. He is also developing minimally invasive devices to deliver drugs into brain tumors.
Behnam Badie, M.D., The Heritage Provider Network Professor in Gene Therapy, professor and chief of the Division of Neurosurgery, received his M.D. from University of California Los Angeles. His research focuses on exploring novel immunotherapeutic strategies through the activation of microglia and macrophages to treat malignant brain tumors. He is also developing minimally invasive devices to deliver drugs into brain tumors.
Mark Boldin, M.D., Ph.D.
Mark. Boldin, M.D., Ph.D., associate professor in the Department of Molecular and Cellular Biology, received his M.D. from Pirogov Russian National Medical Research University in Moscow and his Ph.D. from Weizmann Institute of Science in Israel. His current research focuses on defining the contribution of both microRNAs and long noncoding RNAs to the regulation of gene expression during hematopoiesis and the activation of immune responses.
Mark. Boldin, M.D., Ph.D., associate professor in the Department of Molecular and Cellular Biology, received his M.D. from Pirogov Russian National Medical Research University in Moscow and his Ph.D. from Weizmann Institute of Science in Israel. His current research focuses on defining the contribution of both microRNAs and long noncoding RNAs to the regulation of gene expression during hematopoiesis and the activation of immune responses.
Christine Brown, Ph.D.
Christine Brown, Ph.D., The Heritage Provider Network Professor in Professor in Immunotherapy and professor in the Department of Immuno-Oncology, received her Ph.D. from University of California Berkeley. As deputy director of the T Cell Therapeutic Research Laboratory, she provides scientific oversight for the preclinical research program, as well as the development and refinement of CAR T cells.
Christine Brown, Ph.D., The Heritage Provider Network Professor in Professor in Immunotherapy and professor in the Department of Immuno-Oncology, received her Ph.D. from University of California Berkeley. As deputy director of the T Cell Therapeutic Research Laboratory, she provides scientific oversight for the preclinical research program, as well as the development and refinement of CAR T cells.
Elizabeth Lihua Budde, M.D, Ph.D.
Elizabeth Lihua Budde, M.D., Ph.D., associate professor in the Division of Lymphoma, received her M.D. and Ph.D. from Duke University. She is investigating and designing novel means of immunotherapy for patients with lymphoma and leukemia.
Elizabeth Lihua Budde, M.D., Ph.D., associate professor in the Division of Lymphoma, received her M.D. and Ph.D. from Duke University. She is investigating and designing novel means of immunotherapy for patients with lymphoma and leukemia.
Michael Caligiuri, M.D.
Michael Caligiuri, M.D., the Deana and Steve Campbell Physician-in-Chief Distinguished Chair, president of City of Hope National Medical Center and physician in chief, received his M.D. from Stanford University. His team focuses on the development and activation of natural killer cells for the treatment of leukemia, myeloma and glioblastoma.
Michael Caligiuri, M.D., the Deana and Steve Campbell Physician-in-Chief Distinguished Chair, president of City of Hope National Medical Center and physician in chief, received his M.D. from Stanford University. His team focuses on the development and activation of natural killer cells for the treatment of leukemia, myeloma and glioblastoma.
Mingye Feng, Ph.D.
Mingye Feng, Ph.D., assistant professor in the Department of Immuno-Oncology, received his Ph.D. from Johns Hopkins School of Medicine. His research is directed at understanding the mechanisms of macrophage-mediated immunosurveillance with the ultimate goal of developing novel anti-cancer immunotherapies.
Mingye Feng, Ph.D., assistant professor in the Department of Immuno-Oncology, received his Ph.D. from Johns Hopkins School of Medicine. His research is directed at understanding the mechanisms of macrophage-mediated immunosurveillance with the ultimate goal of developing novel anti-cancer immunotherapies.
Stephen Forman, M.D.
Stephen Forman, M.D., professor in the Department of Hematology & Hematopoietic Cell Transplantation and director of the Hematologic Malignancies Research Institute, received his M.D. from the University of Southern California. His research is focused on developing genetically engineered CAR T cells to promote adoptive immunotherapy in the treatment of a wide range of cancers.
Stephen Forman, M.D., professor in the Department of Hematology & Hematopoietic Cell Transplantation and director of the Hematologic Malignancies Research Institute, received his M.D. from the University of Southern California. His research is focused on developing genetically engineered CAR T cells to promote adoptive immunotherapy in the treatment of a wide range of cancers.
Marcin Kortylewski, Ph.D.
Marcin Kortylewski, Ph.D., professor in the Department of Immuno-Oncology, received his Ph.D. from the University School of Medical Sciences, Poznan, Poland. His research is directed at developing a novel oligonucleotide approach to specifically target immune cells associated with tumors and attenuate STAT3's activity in promoting tumor growth.
Marcin Kortylewski, Ph.D., professor in the Department of Immuno-Oncology, received his Ph.D. from the University School of Medical Sciences, Poznan, Poland. His research is directed at developing a novel oligonucleotide approach to specifically target immune cells associated with tumors and attenuate STAT3's activity in promoting tumor growth.
Peter Lee, M.D.
Peter Lee, M.D., the Bill and Audrey L. Wilder Professor in Cancer Immunotherapeutics, professor and chair of the Department of Immuno-Oncology, received his M.D. from University of California San Diego. His team utilizes high-dimensional flow cytometry, quantitative spatial image analysis and next-generation genomics to dissect how cancer impacts host immune responses in patients, and to develop novel treatments to restore their immune function.
Peter Lee, M.D., the Bill and Audrey L. Wilder Professor in Cancer Immunotherapeutics, professor and chair of the Department of Immuno-Oncology, received his M.D. from University of California San Diego. His team utilizes high-dimensional flow cytometry, quantitative spatial image analysis and next-generation genomics to dissect how cancer impacts host immune responses in patients, and to develop novel treatments to restore their immune function.
Edwin Manuel, Ph.D.
Edwin Manuel, Ph.D., assistant professor in the Department of Immuno-Oncology, received his Ph.D. from Harvard University. He is interested in understanding the escape mechanisms used by tumors to avoid immune recognition. He also developed a novel shRNA technology to down-regulate enzymes that contributes to immune suppression to improve immunotherapy.
Edwin Manuel, Ph.D., assistant professor in the Department of Immuno-Oncology, received his Ph.D. from Harvard University. He is interested in understanding the escape mechanisms used by tumors to avoid immune recognition. He also developed a novel shRNA technology to down-regulate enzymes that contributes to immune suppression to improve immunotherapy.
Saul Priceman, Ph.D., assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, received his Ph.D. from University of California Los Angeles. His laboratory focuses on developing CAR T therapies for solid tumors and optimizing novel T cell engineering approaches for clinical translation.
Srivdya Swaminathan, Ph.D., assistant professor in the Department of Systems Biology, received her Ph.D. from the University of Southern California. Her lab focuses on identifying non-cytotoxic and targeted immunotherapies for treating oncogene addicted B and T cell malignancies driven by genomic rearrangements.
Zuoming Sun, Ph.D.
Zuoming Sun, Ph.D., professor in the Department of Immunology & Theranostics, received his Ph.D. from Duke University. His research team focuses on understanding the mechanisms responsible for the regulation of T cell activation so as to develop effective and safe treatments for immune disorders.
Zuoming Sun, Ph.D., professor in the Department of Immunology & Theranostics, received his Ph.D. from Duke University. His research team focuses on understanding the mechanisms responsible for the regulation of T cell activation so as to develop effective and safe treatments for immune disorders.
Xiuli Wang, Ph.D., research professor in the Department of Hematology & Hematopoietic Cell Transplantation, received her Ph.D. from the University of Oslo. Her work focuses on pre-clinical and translational research on CAR T cell therapy for hematological malignancy and HIV.
Hua Yu, Ph.D.
Hua Yu, Ph.D., the Billy and Audrey L. Wilder Professor in Tumor Immunotherapy and professor in the Department of Immuno-Oncology, received her Ph.D. from Columbia University. Her research team examines the role of STAT3 in mediating the tumor microenvironment. The eventual goal is to devise therapies to target STAT3 leading to tumor death.
Hua Yu, Ph.D., the Billy and Audrey L. Wilder Professor in Tumor Immunotherapy and professor in the Department of Immuno-Oncology, received her Ph.D. from Columbia University. Her research team examines the role of STAT3 in mediating the tumor microenvironment. The eventual goal is to devise therapies to target STAT3 leading to tumor death.
Jianhua Yu, Ph.D.
Jianhua Yu, Ph.D., professor in the Department of Hematology & Hematopoietic Cell Transplantation, received his Ph.D. from Purdue University. His research team focuses on engineering CAR Natural Killer cells, CAR T cells, oncolytic virus and bispecific antibodies, natural product-based strategies and hematopoietic cell transplantation for cancer therapy.
Jianhua Yu, Ph.D., professor in the Department of Hematology & Hematopoietic Cell Transplantation, received his Ph.D. from Purdue University. His research team focuses on engineering CAR Natural Killer cells, CAR T cells, oncolytic virus and bispecific antibodies, natural product-based strategies and hematopoietic cell transplantation for cancer therapy.
Defu Zeng, Ph.D.
Defu Zeng, Ph.D., professor in the Department of Immunology & Theranostics, received his Ph.D. from Fujian Medical University. His laboratory focuses on understanding the pathogenesis of graft-versus-host disease, which is a major obstacle in allogenic hematopoietic cell transplantation for the treatment of hematological malignancies.
Defu Zeng, Ph.D., professor in the Department of Immunology & Theranostics, received his Ph.D. from Fujian Medical University. His laboratory focuses on understanding the pathogenesis of graft-versus-host disease, which is a major obstacle in allogenic hematopoietic cell transplantation for the treatment of hematological malignancies.